Macrocyclic fused pyrazoles as Mcl-1 inhibitors

US12319703B2 · kind B2 · utility

Assignees

• ASCENTAGE PHARMA (SUZHOU) CO., LTD. · CN
• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US
• ASCENTAGE PHARMA GROUP CORP LIMITED · CN

Inventors

• Guozhi Tang · Shanghai, CN
• Dongbo Li · Suzhou, CN
• Liugen Li · Suzhou, CN
• Xianchan Zha · Suzhou, CN
• Wenming Chen · Xinmin, CN
• Shaomeng Wang · Saline, US
• Chao-Yie Yang · Hangzhou City, CN

Key dates

• Filing date: Jan 22, 2020
• Grant date: Jun 3, 2025
• Expiry date: Sep 1, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.